Abstract
IntroductionIn this study, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of different doses of tigecycline in the treatment of VAP caused by multi-resistant bacteria.Material and methodsTo identify relevant studies, we conducted a comprehensive search of multiple databases including theThrough Cochrane libraryLibrary, Embase, PubMed, Chinese biomedical literature database, CNKI, Chinese JP, and WP, covering the period up to the database until December 2022. We assessed the quality of the included studies using the Jadad quality score, and performed a meta-analysis of the data using Stata software.ResultsThere was no clinical heterogeneity or statistical heterogeneity between studies, and a fixed-effect model was used to incorporate the effect size. The incidence of adverse effects in the observed group was not different from that of the control group. The clinical effect of the observation group was significantly better than that of the control group . Meta-analysis of the adverse effects showed that there was no clinical heterogeneity or statistical heterogeneity between studies, and a fixed-effect model was used to incorporate the effect size. The incidence of adverse effects in the observed group was not different fromsimilar to that of the control group.The included articles were tested for publication bias using funnel plot and Egger's test, and none of the four articles had adverse effects as effect indicators.ConclusionsHigh-dose duration of tigecycline treatment for ventilator-related pneumonia caused by multi-resistant bacteria has is associated with improved better clinical efficacy with noout an increase in adverse effectsand high safety.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
